more important in the diagnosis. Its negative predictive value is very high and contributes to the selection of individuals who need serological monitoring and helps in diagnosis in cases with negative serologic tests but positive biopsy results and symptoms. 7 It also contributes to the diagnosis of patients who had begun the diet without diagnosis. 8 The new guidelines published by the European Pediatric Gastroenterology Hepatology and Nutrition Society (ESPGHAN) in 2012 removed the need of biopsy in children who have EMA positivity, specific HLA haplotype, evident symptoms, and tissue transglutaminase (TTG) antibody levels 10 times higher than the transglutaminase (tTG) threshold levels. This new algorithm removes the need for costly, laborious, and invasive endoscopic and histopathologic examinations in some cases. 9 This study aimed to investigate the contribution of the specific HLA type, EMA positivity, tissue transglutaminase (TTG) antibody to the diagnosis of CD in adult patients identified according to the ESPGHAN criteria.
| MATERIAL S AND ME THODS

| Patients and control groups
Patients were referred to the gastroenterology clinic because of the gastrointestinal symptoms (diarrhea, weight loss, constipation, abdominal distension, nausea, vomiting, abdominal pain) and extraintestinal symptoms associated with CD (iron deficiency).
Exclusion criteria included patients malignancy, pregnant women, and Crohn's disease. After exclusion criteria applied, 39 patients (aged constituted the study population. Patients' weights and heights were measured and body mass indexes (BMI) were calculated [body weight/(height (m)) 2 ]. For this group, CD serologic tests (total IgA, anti-tTG IgA, anti-tTG IgG, anti-DGP-IgA, anti-DGP-IgG, and EMA), CD HLA typing, endoscopy, and pathologic examination were performed. All the patients gave written informed consent to participate, and the study was approved by Local Ethics Committee of a University Hospital.
| Control group
Serological tests were performed in 43 control patients who underwent upper gastrointestinal system endoscopy with initial diagnosis other than CD, and with the aid of endoscopic and clinical findings, CD was excluded. These test results were used in assessing the diagnostic performance of serological tests.
In addition, our study included tissue typing results of unrelated bone marrow donors without immune-related diseases who applied to tissue typing laboratory for tissue type determination. Donors' demographic findings were similar with the patient group and their results demonstrated the frequency of DQ types in Turkish society.
The tissue typing results of the study group were compared with these results.
| Serological tests
In our study, total IgA levels in serum samples were studied by neph- 
| HLA genotyping
| Upper endoscopy and histological analysis
Upper gastrointestinal endoscopy was performed and more than one duodenal biopsy specimens lll were taken from the second part of the duodenum (Fujinon, Japan). Samples were evaluated by single pathologist.
The histological patterns were evaluated according to Marsh- is also characterized by a partial (IIIa), subtotal (IIIb), or total (IIIc) villous atrophy, and type IV is represented by villous atrophy alone. 10 Simple scoring system that listed in ESPGHAN was performed for our patients. The scoring system takes into account four items
which are symptoms, antibodies, HLA tissue types, and biopsy findings. To make the final diagnosis, a sum of four points is required. 
| Statistical analysis
Statistical analyses were performed by using the SPSS version 21.0 (Statistical Package for Social Science; Chicago, IL). Categorical data were compared by using chi-square and Fisher's exact tests.
Spearman's correlation analysis test was used to evaluate the correlation between quantitative antibody and Marsh score results. ROC analysis was used to reach optimum sensitivity and specificity levels.
Sensitivity, specificity, and positive and negative predictive values were detected according to the evaluation of the patients with clinical situation and gold standard diagnostic tests.
| RE SULTS
Seventeen patients out of 39 patients who applied to outpatient clinics with severe malabsorption symptoms were enrolled in the study. The remaining patients presented with either other CD-relevant symptoms or asymptomatic. Demographic and clinical data of all groups in the study are summarized in Tables 1 and 2 .
There was no IgA-deficient case in any group. Anti-tTG IgA was positive in 21 patients, and all of the anti-tTG IgA-positive patients were EMA positive also. Twenty-six patients were either DQ2 or DQ8 positive, eight patients presented half DQ2 (DQ2.2 or DQ7), and five patients were both HLA-DQ2 and DQ8 negative.
Twenty-three patients had intestinal villous atrophy (six patients type IIIa, four patient type IIIb, 10 patients type IIIc, three patient type IV). The remaining 16 patients were reported as normal villous architecture (type 0-1). Three patients, who had a diagnosis of Marsh 3a score in biopsy specimens, were finally diagnosed as CD negative.
HLA typing and serological results of CD diagnosed and CD excluded groups were summarized in Table 3 .
In control group, positive serological test results were as follows:
anti-IgA tTG, anti-IgG tTG, and anti-IgA DGP tests were positive in one patient, IgG DGP in two patients, and the rest were serology negative. Clinical and endoscopic findings did not support the serological results so we accepted them as false positive. No EMA false positivity was detected in control group (Table 3) .
In regard to the relation of serological test results with tissue injury, the strongest correlation was obtained between anti-IgAtTG (ρ = 0.71) and Marsh scores among the studied serological tests (Table 4) .
| Diagnostic performance of serological tests
For the evaluation of the diagnostic performance of serological tests, the gold standard biopsy, serological tests, and clinical findings were all taken into consideration for the definite CD diagnosis. According to the threshold of the manufacturer, anti-tTG IgA sensitivity was 100%; specificity was 98.4%. Anti-EMA sensitivity was 100%; specificity was 100%. By ROC curve analysis, the best diagnostic specificity result of anti-tTG IgA was detected with a threshold value of 1.6-fold higher (>32.8 IU/mL) than the threshold of the manufacturer (20 IU/mL). When ESPGHAN's threshold value for children was taken into consideration in our adult group (>200 IU/mL), the sensitivity decreased to 81% (Table 5) .
Celiac disease and control groups were compared in terms of HLA tissue types. DQ2.5 homozygous or DQ2.5/DQ2.2 was significantly higher in CD group and DQ2-and DQ8-negative HLA tissue types were significantly higher in control group (Table 6 ).
Celiac excluded and control groups were compared in terms of HLA tissue types. DQ 2.5 homozygous or DQ2.5/DQ2.2 was significantly higher in CD excluded group. There was no significant difference between these two groups in terms of other HLA tissue types (Table 6 ).
Celiac disease and CD excluded groups were compared in terms of HLA tissue types. There was no significant difference between these two groups in terms of HLA tissue types (Table 6 ).
In Figure 1 , the algorithm for CD diagnosis according to ESPGHAN criteria was illustrated. In regard to the results, 15 patients could be diagnosed without biopsy according to the ESPGHAN criteria.
Symptoms, autoimmune antibodies, and HLA tissue types were taken into consideration. Fifteen patients fulfilled four diagnostic criteria so we assume that these patients could be diagnosed without biopsy.
In Figure 2 , the algorithm of the patients whose serology tests were negative was demonstrated. Among these, 10 patients were presented with malabsorption syndrome or HLA-DQ2 or DQ8 positive, so biopsy may be applied for these patients to exclude CD. For the remaining eight patients, CD can be excluded without biopsy (Figure 2 ).
| D ISCUSS I ON
Celiac disease presentation and symptoms are highly variable. It has a wide clinical spectrum from the classical form with severe malabsorption to the silent form which is found incidentally with serologic screening.
The disease resembles the iceberg model because today more asymptomatic cases are diagnosed with the increasing number of public screenings than symptomatic cases. 11 Significant changes have been observed in disease prevalence especially in the last fifty years. Individuals with normal body mass indexes were also had CD diagnosis. It was found that 25% of adult patients who had CD diagnosis were older than 60 years. 12 The mean age of patients in this study's CD group was 34.9 ± 14 (19-66).
It is revealed that asymptomatic and atypical manifestations make up the majority of cases in adult patients. 13 For example, anemia can be seen as the only symptom. 14 Similarly, more than 50% of our patients were presented with atypical clinical symptoms.
In 1983, Chorzelski and co-workers first used the EMA test which was the first non-invasive test for CD diagnosis. 15 In 1997, Dieterich and colleagues defined tTG antigen, which is the target of the EMA antibody. Since the ELISA test is easy to apply, suitable for automation, standardized, the tTG antibody tests have become popular in a short time. 16 High titers of anti-tTG IgA levels have been defined to be an important indicator of histopathologic damage in a number of previous studies. In a multicenter study held in pediatric patient group, a high tTG antibody level indicated severe intestinal damage. 17 Barker et al 18 similarly showed in a group of children with CD that very high titers of tTG could remove the need for biopsy. In another study, patients with tTG antibody levels above 100 U/mL, the histopathologic results were statistically more severe from patients tTG levels below 100 U/mL. 19 As a re- Simple scoring system that is listed in EPSGHAN is performed for our adult patients. Symptoms, antibodies, and HLA tissue types were taken into consideration. As a result, 15 patients were determined as they could be diagnosed without biopsy. In addition, exclusion of CD can be made according to ESPGHAN criteria. In our CD excluded group, eight patients were presented with negative serology, 50% DQ2 positive or HLA-DQ2/8 negative and different clinic from malabsorption syndrome. With these given, CD diagnosis exclusion can be done without biopsy.
TA B L E 4 Correlation of antibody levels with Marsh Scores
In 2014, the guidelines for adult CD states that biopsy is an essential part of adult age group and serology could not take its place, but this guide was not widely accepted. 20 There is no stan- 
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According to the threshold of the manufacturer, anti-tTG IgA sensitivity was 100%; specificity was 98.4%. EMA sensitivity was 100%; specificity was 100%. By ROC curve analysis, the best diagnostic specificity result of anti-tTG IgA was detected with a threshold value of 1.6-fold higher (> 32.8 IU/mL) than the threshold of the manufacturer (20 IU/mL). When ESPGHAN's threshold value for children was taken into consideration (>200 IU/mL), it was found that the sensitivity decreased to 81%. Similarly, in a study of adult patients in which the threshold value was determined by ROC curve analysis, with the determined anti-tTG IgA threshold (>3.6-fold higher), the highest sensitivity (76.8%) was achieved but the sensitivity decreased to 33.5% when the threshold value recommended for children was used. 24 In a meta-analysis involving 34 studies, it has been shown that EMA had a higher specificity when compared with tTG. 16 Although EMA is nonautomated, labor-intensive, and relatively expensive, 16, 25 this serologic test had the highest sensitivity and specificity in our study. In our control group, IgA tTG false positivity was detected in a patient, but EMA false positivity was not detected.
This study put forth that EMA is the test with highest diagnostic accuracy to determine patients who can be diagnosed without biopsy.
In our study, the PPV of EMA and ıgATTG were 100% and 95.5% Biopsy must be applied for these patient respectively. Therefore, we put forward that at least two autoimmune serological parameters, like TTG and EMA, must be studied together for the diagnosis of CD to obtain highest sensitivity and specificity and avoid false-positive results although it is found to be less than 5% in our study.
Villousatrophy is reported in other diseases. For example, infections such as severe rotavirus enteritis, giardiasis, HIV enteropathy, tropical sprue, Crohn's disease, eosinophilic gastroenteritis, cow's milk enteropathy, soy protein enteropathy can cause villous atrophy. 26 In a study, immunocompetent adults' clinicopathologic findings that presented with villous flattening were evaluated. Initially, they were thought to have CD but none responded to gluten-free diet and Cd serological tests were negative. In these cases, viral gastroenteritis was thought to cause pathological injury. 27 In another study, 15 patients with intestinal atrophy but negative EMA results were enrolled. Thirteen patients were finally excluded from CD. Two patients were under two years so they did not develop immune response. This led to false-negative results. 28 Three of our patients that presented with villous atrophy were accepted as CD negative. The real reason of the pathological injury could not be revealed.
Most CD patients possess the genotype HLA-DQ2.5 (simplified to HLA-DQ2) and HLA-DQ8. The other genotypes associated with CD are half the HLA-DQ2.5 genotype, most commonly DQ2.2 and rarely DQ7. 29 In a European study, it was detected that 88% of patients' genotype was DQ2.5, 6% was HLA-DQ8%, and 5.6% was one half of the HLA-DQ2.5 (4% DQ2.2, 1.6% DQ7). 30 In our study, In a study comparing children and adult CD patients, typical gastrointestinal symptoms were significantly higher in the pediatric patient group (P = 0.01). There was also a significant age-related decrease in tTG antibody level (P < 0.001) and villous atrophy (P < 0.001). It has been shown that in adult patients, both clinical and histopathologic severity of illness and tTG antibody levels are lower. 4 When we used the recommended threshold value for children (200 IU/mL), sensitivity decreased to 81%. For this reason, while creating an ESPGHAN-like algorithm for adult patients, it
should be taken into consideration that, the clinical, serological, and tissue damage levels are different from pediatric patients, so
the cutoff values of the serological tests also differ. Our results
were consistent with the study of Tola et al 24 that different threshold levels for pediatric and adult patients must be detected for IgA tTG levels.
One of the benefits of this study is the comparison of the prevalence of HLA-DQ positivity in CD and healthy population.
To our knowledge, the only limitation of this study is the limited number of CD patients. For this reason, larger and multicenter studies are needed to confirm the new diagnostic algorithm of adult CD 
